During the past 12 months, Lumos Diagnostics Holdings's average Book Value Per Share Growth Rate was -52.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -51.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Lumos Diagnostics Holdings was -51.50% per year. The lowest was -51.50% per year. And the median was -51.50% per year.
During the past 4 years, the highest P/B Ratio of Lumos Diagnostics Holdings was 24.62. The lowest was 0.10. And the median was 1.57.
Lumos Diagnostics Holdings (ASX:LDX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Lumos Diagnostics Holdings Book Value per Share Related Terms
Lumos Diagnostics Holdings Book Value per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings Book Value per Share Chart
ASX:LDX vs ABT, SYK, MDT: Book Value per Share Comparison
For the Medical Devices subindustry, Lumos Diagnostics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings (ASX:LDX) has a Book Value per Share of A$0.01 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Lumos Diagnostics Holdings and its competitors.
Is Lumos Diagnostics Holdings' Book Value per Share too high?
Lumos Diagnostics Holdings' current Book Value per Share is A$0.01.
How does Lumos Diagnostics Holdings' Book Value per Share compare to ABT and SYK?
Lumos Diagnostics Holdings' Book Value per Share of A$0.01 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Medical Devices & Instruments company?
A good Book Value per Share depends on the Medical Devices & Instruments industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Lumos Diagnostics Holdings and its competitors. Lumos Diagnostics Holdings's current Book Value per Share is A$0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.10 — trading 390% above its estimated fair value. The current Book Value per Share is A$0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Book Value per Share is A$0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 